Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 25Other hematologic neoplasm 7Plasma cell 3

Conditions

Multiple Myeloma 36Neoplasms, Plasma Cell 8Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Intraocular Lymphoma 2Immunoglobulin Light-chain Amyloidosis 2Immunoblastic Lymphadenopathy 2Burkitt Lymphoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Renal Insufficiency, Chronic 1Renal Insufficiency 1Proteostasis Deficiencies 1

Interventions

Dexamethasone 109pomalidomide 53Cyclophosphamide 52Bortezomib 42fludarabine phosphate 33Lenalidomide 33Peripheral Blood Stem Cell Transplantation 28carfilzomib 26Mycophenolic Acid 25daratumumab 24Calcium Dobesilate 24Cyclosporine 22Busulfan 21Antilymphocyte Serum 20Tacrolimus 19Whole-Body Irradiation 18Melphalan 17Radiotherapy 15Filgrastim 15Methotrexate 14fludarabine 12Methylprednisolone 12elotuzumab 11Cord Blood Stem Cell Transplantation 11selinexor 10ixazomib 9Etoposide 8Thalidomide 7Prednisone 7Panobinostat 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × Bendamustine Hydrochloride × Plasma cell × Clear all
NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Sun Yat-sen University

Phase 1/2 Unknown
56 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01526694 2018-07-03

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Azienda Ospedaliera di Bolzano

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01686386 2013-04-05

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Gruppo Italiano Studio Linfomi

Phase 1/2 Unknown
60 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡